MiniMed (MMED) Q1 FY2027 earnings

Reported results

• Worldwide net sales of $843 million grew 16.6% as reported and 15.8% organic, including an approximate 4-6% benefit from extra week
• U.S. net sales of $240 million grew 13.1% as reported and organic; U.S. New Pumps Sold grew over 20% year over year
• International net sales of $603 million grew 18.1% as reported and 16.9% organic
• Worldwide New Pumps Sold of approximately 34,000, an increase of 7.7% year over year
• Worldwide CGM Attachment Rate of 69%, an increase of approximately 100 basis points quarter over quarter
• GAAP net income attributable to the Company of $0 million (compared to net loss of $19 million in Q1 FY2026)

Guidance

• FY2027 organic revenue growth of approximately 10.5%, which includes the approximate 1.0 to 1.5% benefit from the extra week in Q1 FY27, raised from prior guidance of approximately 10%
• FY2027 adjusted EBITDA margin of approximately 16%, reaffirming prior guidance

Notes

The company presents both GAAP and non-GAAP organic revenue growth metrics. Reported figures include currency impacts and Italian payback accrual adjustments; organic figures exclude these items. The extra week benefit from the 52-53 week fiscal calendar is separately quantified.

Price and volatility reaction

The stock moved +10.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -8.7 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-09-01 (8-K, Item 2.02). Read the original filing on sec.gov.